[1] S. Blouin, T. D. Craggs, D. A. Lafontaine and J. C. Penedo, “Functional Studies of DNA-Protein Interactions Using FRET Techniques,” Methods in Molecular Biology, Vol. 543, 2009, pp. 475-502. http://dx.doi.org/10.1007/978-1-60327-015-1_28
[2] D. J. King, S. E. Bassett, X. Li, S. A. Fennewald, N. K. Herzog, B. A. Luxon, R. Shope and D. G. Gorenstein, “Combinatorial Selection and Binding of Phosphorothioate Aptamers Targeting Human NF-Kappa B RelA (p65) and p50,” Biochemistry, Vol. 41, No. 30, 2002, pp. 9696-9706. http://dx.doi.org/10.1021/bi020220k
[3] G. Courtois and T. D. Gilmore, “Mutations in the NF-κB Signaling Pathway: Implications for Human Disease,” Oncogene, Vol. 25, 2006, pp. 6831-6843.
[4] M. Karin, “Nuclear Factor-κB in Cancer Development and Progression,” Nature, Vol. 441, 2006, pp. 431-436. http://dx.doi.org/10.1038/nature04870
[5] R. G. Baker, M. S. Hayden and S. Ghosh, “NF-κB, Inflammation and Metabolic Disease,” Cell Metabolism, Vol. 13, No. 1, 2011, pp. 11-22. http://dx.doi.org/10.1016/j.cmet.2010.12.008
[6] A. Kumar, Y. Takada, A. M. Boriek and B. Aggarwal, “Nuclear Factor-κB: Its Role in Health and Disease,” Journal of Molecular Medicine, Vol. 82, No. 7, 2004, pp. 434-448. http://dx.doi.org/10.1007/s00109-004-0555-y
[7] N. D. Perkins, “Integrating Cell-Signalling Pathways with NF-κB and IKK Function,” Nature Reviews Molecular Cell Biology, Vol. 8, No. 1, 2007, pp. 49-62. http://dx.doi.org/10.1038/nrm2083
[8] F. Arenzana-Seisdedos, P. Turpin, M. Rodriguez, et al., “Nuclear Localization of IkBa Promotes Active Transport of NF-kB from the Nucleus to the Cytoplasm,” Journal of Cell Science, Vol. 110, 1997, pp. 369-378.
[9] Gel Shift Assays—EMSA, Protein Methods Library, Thermo Scientific.
[10] C. W. Muller and S. C. Harrison, “The Structure of the NF-Kappa B p50: DNA-Complex: A Starting Point for Analyzing the Rel Family,” FEBS Letter, Vol. 369, No. 1, 1995, pp. 113-117. http://dx.doi.org/10.1016/0014-5793(95)00541-G
[11] TR-FRET Basics. CISBIO Bioassays.
[12] J. Paulo, “BIACORE T100: An Overview of Underlying Concepts, Basic Operation, Experimental Techniques and Potential Applications,” JP Biacore Presentation, 071106.
[13] L. Beaudet, R. Rodriguez-Suarez, M. H. Venne, M. Caron, J. Bedard, V. Brechler, S. Parent and M. Bielefeld-Sevigny, “AlphaLISA Immunoassays: The No-Wash Alternative to ELISAs for Research and Drug Discovery,” Nature Methods, Vol. 5, 2008.
[14] PerkinElmer’s AlphaLISA. Bead Selection and Bead Interference—Assay Support Knowledge Base.
[15] R. Eglen and S. Howland, “AlphaLISA in Biomarker Detection for Drug Discovery,” Technology & Services Section, PerkinElmer, Inc.
[16] D. E. Volk, X. Yang, S. M. Fennewald, D. J. King, S. Bassett, S. Venkitachalam, N. Herzog, B. A. Luxon and D. G. Gorenstein, “Solution Structure and Design of Dithiophosphate Backbone Aptamers Targeting Transcription Factor NF-Kappa B,” Bioorganic Chemistry, Vol. 30, No. 6, 2002, pp. 396-419. http://dx.doi.org/10.1016/S0045-2068(02)00510-2
[17] T. Fujita, G. P. Nolan, S. Ghosh and D. Baltimore, “Independent Modes of Transcriptional Activation by the p50 and p65 Subunits of NF-Kappa B,” Genes & Development, Vol. 6, 1992, pp. 775-787. http://dx.doi.org/10.1101/gad.6.5.775
[18] D. Thanos and T. Maniatis, “The High Mobility Group Protein HMG I (Y) Is Required for NF-Kappa B-Dependent Virus Induction of the Human IFN-Beta Gene,” Cell, Vol. 71, No. 5, 1992, pp. 777-789. http://dx.doi.org/10.1016/0092-8674(92)90554-P
[19] PerkinElmer’s AlphaLISA. Determining KD with an Alpha Assay.
[20] PerkinElmer’s AlphaLISA. The Hook Effect—Assay Support Knowledge Base.